Multiple Sclerosis Biomarker Candidates Revealed by Cell-Type-Specific Interactome Analysis

dc.contributor.authorYurduseven, Kubra
dc.contributor.authorBabal, Yigit Koray
dc.contributor.authorCelik, Esref
dc.contributor.authorKerman, Bilal Ersen
dc.contributor.authorKurnaz, Isil Aksan
dc.date.accessioned2025-10-29T11:16:24Z
dc.date.issued2022
dc.departmentEnstitüler, Lisansüstü Eğitim Enstitüsü, Biyomühendislik Ana Bilim Dalı
dc.description.abstractMultiple sclerosis (MS) is a demyelinating disorder that affects multiple regions of the central nervous system such as the brain, spinal cord, and optic nerves. Susceptibility to MS, as well as disease progression rates, displays marked patient-to-patient variability. To date, biomarkers that forecast differences in clinical phenotypes and outcomes have been limited. In this context, cell-type-specific interactome analyses offer important prospects and hope for novel diagnostics and therapeutics. We report here an original study using bioinformatic analysis of MS data sets that revealed interaction profiles as well as specific hub proteins in white matter (WM) and gray matter (GM) that appear critical for disease mechanisms. First, cell-type-specific interactome analyses suggested that while interactions within the WM were focused on oligodendrocytes, interactions within the GM were mostly neuron centric. Second, hub proteins such as APP, EGLN3, PTEN, and LRRK2 were identified to be differentially regulated in MS data sets. Lastly, a comparison of the brain and peripheral blood samples identified biomarker candidates such as NRGN, CRTC1, CDC42, and IFITM3 to be differentially expressed in different types of MS. These findings offer a unique cell-type-specific cell-to-cell interaction network in MS and identify potential biomarkers by comparative analysis of the brain and the blood transcriptomics. From a study design and methodology perspective, we suggest that the cell-type-specific interactome analysis is an important systems science frontier that might offer new insights on other neurodegenerative and brain disorders as well.
dc.identifier.doi10.1089/omi.2022.0023
dc.identifier.endpage317
dc.identifier.issn1536-2310
dc.identifier.issn1557-8100
dc.identifier.issue5
dc.identifier.orcid0000-0001-9954-4435
dc.identifier.orcid0000-0003-1106-3288
dc.identifier.pmid35483054
dc.identifier.scopus2-s2.0-85130002702
dc.identifier.scopusqualityQ2
dc.identifier.startpage305
dc.identifier.urihttps://doi.org/10.1089/omi.2022.0023
dc.identifier.urihttps://hdl.handle.net/20.500.14854/7561
dc.identifier.volume26
dc.identifier.wosWOS:000792498600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofOmics-A Journal of Integrative Biology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20251020
dc.subjectmultiple sclerosis
dc.subjectinteractome
dc.subjectbiomarkers
dc.subjectpersonalized medicine
dc.subjectneurodegenerative diseases
dc.subjectmolecular targets
dc.titleMultiple Sclerosis Biomarker Candidates Revealed by Cell-Type-Specific Interactome Analysis
dc.typeArticle

Dosyalar